( ||| S:0 E:1 ||| -LRB-
1 ||| S:1 E:2 ||| LS
) ||| S:2 E:3 ||| -RRB-
H-magnetic  ||| S:3 E:14 ||| JJ
resonance  ||| S:14 E:24 ||| NN
spectroscopy  ||| S:24 E:37 ||| NN
in  ||| S:37 E:40 ||| IN
social  ||| S:40 E:47 ||| JJ
anxiety  ||| S:47 E:55 ||| NN
disorder  ||| S:55 E:64 ||| NN
Social  ||| S:64 E:71 ||| NNP
anxiety  ||| S:71 E:79 ||| NN
disorder  ||| S:79 E:88 ||| NN
( ||| S:88 E:89 ||| -LRB-
SAD ||| S:89 E:92 ||| NNP
)  ||| S:92 E:94 ||| -RRB-
is  ||| S:94 E:97 ||| VBZ
characterized  ||| S:97 E:111 ||| VBN
by  ||| S:111 E:114 ||| IN
excessive  ||| S:114 E:124 ||| JJ
anxiety  ||| S:124 E:132 ||| NN
about  ||| S:132 E:138 ||| IN
social  ||| S:138 E:145 ||| JJ
interaction  ||| S:145 E:157 ||| NN
or  ||| S:157 E:160 ||| CC
performance  ||| S:160 E:172 ||| NN
situations ||| S:172 E:182 ||| NNS
,  ||| S:182 E:184 ||| ,
leading  ||| S:184 E:192 ||| VBG
to  ||| S:192 E:195 ||| TO
avoidance  ||| S:195 E:205 ||| VB
and  ||| S:205 E:209 ||| CC
clinically  ||| S:209 E:220 ||| RB
significant  ||| S:220 E:232 ||| JJ
distress ||| S:232 E:240 ||| NN
.  ||| S:240 E:242 ||| .
A  ||| S:242 E:244 ||| DT
growing  ||| S:244 E:252 ||| VBG
literature  ||| S:252 E:263 ||| NN
on  ||| S:263 E:266 ||| IN
the  ||| S:266 E:270 ||| DT
neurobiology  ||| S:270 E:283 ||| NN
of  ||| S:283 E:286 ||| IN
SAD  ||| S:286 E:290 ||| NNP
has  ||| S:290 E:294 ||| VBZ
suggested  ||| S:294 E:304 ||| VBN
that  ||| S:304 E:309 ||| IN
the  ||| S:309 E:313 ||| DT
reward ||| S:313 E:319 ||| FW
/ ||| S:319 E:320 ||| FW
avoidance  ||| S:320 E:330 ||| FW
basal  ||| S:330 E:336 ||| FW
ganglia  ||| S:336 E:344 ||| FW
circuitry  ||| S:344 E:354 ||| FW
in  ||| S:354 E:357 ||| IN
general  ||| S:357 E:365 ||| JJ
and  ||| S:365 E:369 ||| CC
the  ||| S:369 E:373 ||| DT
glutamatergic  ||| S:373 E:387 ||| JJ
system  ||| S:387 E:394 ||| NN
in  ||| S:394 E:397 ||| IN
particular  ||| S:397 E:408 ||| JJ
may  ||| S:408 E:412 ||| MD
play  ||| S:412 E:417 ||| VB
a  ||| S:417 E:419 ||| DT
role ||| S:419 E:423 ||| NN
.  ||| S:423 E:425 ||| .
In  ||| S:425 E:428 ||| IN
the  ||| S:428 E:432 ||| DT
current  ||| S:432 E:440 ||| JJ
study ||| S:440 E:445 ||| NN
,  ||| S:445 E:447 ||| ,
we  ||| S:447 E:450 ||| PRP
investigated  ||| S:450 E:463 ||| VBD
( ||| S:463 E:464 ||| -LRB-
1 ||| S:464 E:465 ||| LS
) ||| S:465 E:466 ||| -RRB-
H-magnetic  ||| S:466 E:477 ||| FW
resonance  ||| S:477 E:487 ||| FW
spectroscopy  ||| S:487 E:500 ||| FW
( ||| S:500 E:501 ||| -LRB-
( ||| S:501 E:502 ||| -LRB-
1 ||| S:502 E:503 ||| LS
) ||| S:503 E:504 ||| -RRB-
H-MRS ||| S:504 E:509 ||| NNP
)  ||| S:509 E:511 ||| -RRB-
concentrations  ||| S:511 E:526 ||| NNS
in  ||| S:526 E:529 ||| IN
cortical ||| S:529 E:537 ||| NN
,  ||| S:537 E:539 ||| ,
striatal ||| S:539 E:547 ||| NN
,  ||| S:547 E:549 ||| ,
and  ||| S:549 E:553 ||| CC
thalamic  ||| S:553 E:562 ||| JJ
circuitry ||| S:562 E:571 ||| NN
,  ||| S:571 E:573 ||| ,
as  ||| S:573 E:576 ||| RB
well  ||| S:576 E:581 ||| RB
as  ||| S:581 E:584 ||| IN
their  ||| S:584 E:590 ||| PRP$
associations  ||| S:590 E:603 ||| NNS
with  ||| S:603 E:608 ||| IN
measures  ||| S:608 E:617 ||| NNS
of  ||| S:617 E:620 ||| IN
social  ||| S:620 E:627 ||| JJ
anxiety  ||| S:627 E:635 ||| NN
and  ||| S:635 E:639 ||| CC
related  ||| S:639 E:647 ||| JJ
symptoms ||| S:647 E:655 ||| NNS
,  ||| S:655 E:657 ||| ,
in  ||| S:657 E:660 ||| IN
patients  ||| S:660 E:669 ||| NNS
with  ||| S:669 E:674 ||| IN
primary  ||| S:674 E:682 ||| JJ
SAD ||| S:682 E:685 ||| NNP
.  ||| S:685 E:687 ||| .
Eighteen  ||| S:687 E:696 ||| JJ
adult  ||| S:696 E:702 ||| NN
individuals  ||| S:702 E:714 ||| NNS
with  ||| S:714 E:719 ||| IN
SAD  ||| S:719 E:723 ||| NNP
and  ||| S:723 E:727 ||| CC
19  ||| S:727 E:730 ||| CD
age-  ||| S:730 E:735 ||| JJ
and  ||| S:735 E:739 ||| CC
sex-  ||| S:739 E:744 ||| JJ
matched  ||| S:744 E:752 ||| NN
controls  ||| S:752 E:761 ||| VBZ
participated  ||| S:761 E:774 ||| VBN
in  ||| S:774 E:777 ||| IN
this  ||| S:777 E:782 ||| DT
study.  ||| S:782 E:789 ||| NNP
( ||| S:789 E:790 ||| -LRB-
1 ||| S:790 E:791 ||| LS
) ||| S:791 E:792 ||| -RRB-
H-MRS  ||| S:792 E:798 ||| NNP
was  ||| S:798 E:802 ||| VBD
used  ||| S:802 E:807 ||| VBN
to  ||| S:807 E:810 ||| TO
determine  ||| S:810 E:820 ||| VB
relative  ||| S:820 E:829 ||| JJ
metabolite  ||| S:829 E:840 ||| JJ
concentrations  ||| S:840 E:855 ||| NNS
in  ||| S:855 E:858 ||| IN
the  ||| S:858 E:862 ||| DT
anterior  ||| S:862 E:871 ||| FW
cingulate  ||| S:871 E:881 ||| FW
cortex  ||| S:881 E:888 ||| FW
( ||| S:888 E:889 ||| -LRB-
ACC ||| S:889 E:892 ||| NNP
)  ||| S:892 E:894 ||| -RRB-
using  ||| S:894 E:900 ||| VBG
single  ||| S:900 E:907 ||| JJ
voxel  ||| S:907 E:913 ||| JJ
spectroscopy  ||| S:913 E:926 ||| NNS
( ||| S:926 E:927 ||| -LRB-
reporting  ||| S:927 E:937 ||| VBG
relative  ||| S:937 E:946 ||| JJ
N-acetyl-aspartate  ||| S:946 E:965 ||| NN
( ||| S:965 E:966 ||| -LRB-
NAA ||| S:966 E:969 ||| NNP
) ||| S:969 E:970 ||| -RRB-
,  ||| S:970 E:972 ||| ,
N-acetyl-aspartate  ||| S:972 E:991 ||| JJ
with  ||| S:991 E:996 ||| IN
N-acetyl-aspartyl-glutamate  ||| S:996 E:1024 ||| NNP
( ||| S:1024 E:1025 ||| -LRB-
NAA+NAAG ||| S:1025 E:1033 ||| NNP
) ||| S:1033 E:1034 ||| -RRB-
,  ||| S:1034 E:1036 ||| ,
glycerophosphocholine  ||| S:1036 E:1058 ||| VBG
with  ||| S:1058 E:1063 ||| IN
phosphocholine  ||| S:1063 E:1078 ||| NNS
( ||| S:1078 E:1079 ||| -LRB-
GPC+PCh ||| S:1079 E:1086 ||| NNP
) ||| S:1086 E:1087 ||| -RRB-
,  ||| S:1087 E:1089 ||| ,
myo-inositol ||| S:1089 E:1101 ||| NNP
,  ||| S:1101 E:1103 ||| ,
glutamate  ||| S:1103 E:1113 ||| NNS
( ||| S:1113 E:1114 ||| -LRB-
Glu ||| S:1114 E:1117 ||| NNP
) ||| S:1117 E:1118 ||| -RRB-
,  ||| S:1118 E:1120 ||| ,
and  ||| S:1120 E:1124 ||| CC
glutamate  ||| S:1124 E:1134 ||| NN
with  ||| S:1134 E:1139 ||| IN
its  ||| S:1139 E:1143 ||| PRP$
precursor  ||| S:1143 E:1153 ||| JJ
glutamine  ||| S:1153 E:1163 ||| NNS
( ||| S:1163 E:1164 ||| -LRB-
Glu+Gln ||| S:1164 E:1171 ||| NNP
) ||| S:1171 E:1172 ||| -RRB-
) ||| S:1172 E:1173 ||| -RRB-
,  ||| S:1173 E:1175 ||| ,
and  ||| S:1175 E:1179 ||| CC
the  ||| S:1179 E:1183 ||| DT
caudate ||| S:1183 E:1190 ||| NN
,  ||| S:1190 E:1192 ||| ,
putamen  ||| S:1192 E:1200 ||| NN
and  ||| S:1200 E:1204 ||| CC
thalami  ||| S:1204 E:1212 ||| JJ
bilaterally  ||| S:1212 E:1224 ||| NNS
using  ||| S:1224 E:1230 ||| VBG
two  ||| S:1230 E:1234 ||| CD
dimensional  ||| S:1234 E:1246 ||| JJ
chemical  ||| S:1246 E:1255 ||| NN
shift  ||| S:1255 E:1261 ||| NN
imaging  ||| S:1261 E:1269 ||| NN
( ||| S:1269 E:1270 ||| -LRB-
reporting  ||| S:1270 E:1280 ||| VBG
relative  ||| S:1280 E:1289 ||| JJ
NAA+NAAG  ||| S:1289 E:1298 ||| NN
and  ||| S:1298 E:1302 ||| CC
GPC+PCh ||| S:1302 E:1309 ||| CD
) ||| S:1309 E:1310 ||| -RRB-
.  ||| S:1310 E:1312 ||| .
Relationships  ||| S:1312 E:1326 ||| NNS
between  ||| S:1326 E:1334 ||| IN
metabolite  ||| S:1334 E:1345 ||| JJ
concentrations  ||| S:1345 E:1360 ||| NNS
and  ||| S:1360 E:1364 ||| CC
measures  ||| S:1364 E:1373 ||| NNS
of  ||| S:1373 E:1376 ||| IN
social  ||| S:1376 E:1383 ||| JJ
anxiety  ||| S:1383 E:1391 ||| NN
and  ||| S:1391 E:1395 ||| CC
related  ||| S:1395 E:1403 ||| JJ
symptoms  ||| S:1403 E:1412 ||| NNS
were  ||| S:1412 E:1417 ||| VBD
also  ||| S:1417 E:1422 ||| RB
determined ||| S:1422 E:1432 ||| VBN
.  ||| S:1432 E:1434 ||| .
Measures  ||| S:1434 E:1443 ||| NNS
of  ||| S:1443 E:1446 ||| IN
social  ||| S:1446 E:1453 ||| JJ
anxiety  ||| S:1453 E:1461 ||| NN
included  ||| S:1461 E:1470 ||| VBD
symptom  ||| S:1470 E:1478 ||| JJ
severity ||| S:1478 E:1486 ||| NN
,  ||| S:1486 E:1488 ||| ,
blushing  ||| S:1488 E:1497 ||| JJ
propensity ||| S:1497 E:1507 ||| NN
,  ||| S:1507 E:1509 ||| ,
and  ||| S:1509 E:1513 ||| CC
gaze  ||| S:1513 E:1518 ||| JJ
anxiety ||| S:1518 E:1525 ||| NN
/ ||| S:1525 E:1526 ||| CD
avoidance ||| S:1526 E:1535 ||| NN
.  ||| S:1535 E:1537 ||| .
We  ||| S:1537 E:1540 ||| PRP
found ||| S:1540 E:1545 ||| VBD
,  ||| S:1545 E:1547 ||| ,
first ||| S:1547 E:1552 ||| JJ
,  ||| S:1552 E:1554 ||| ,
decreased  ||| S:1554 E:1564 ||| VBD
relative  ||| S:1564 E:1573 ||| JJ
glutamate  ||| S:1573 E:1583 ||| JJ
concentration  ||| S:1583 E:1597 ||| NN
in  ||| S:1597 E:1600 ||| IN
the  ||| S:1600 E:1604 ||| DT
ACC  ||| S:1604 E:1608 ||| NNP
of  ||| S:1608 E:1611 ||| IN
SAD  ||| S:1611 E:1615 ||| NNP
and  ||| S:1615 E:1619 ||| CC
changes  ||| S:1619 E:1627 ||| NNS
in  ||| S:1627 E:1630 ||| IN
myo-inositol  ||| S:1630 E:1643 ||| JJ
with  ||| S:1643 E:1648 ||| IN
measures  ||| S:1648 E:1657 ||| NNS
of  ||| S:1657 E:1660 ||| IN
social  ||| S:1660 E:1667 ||| JJ
anxiety ||| S:1667 E:1674 ||| NN
.  ||| S:1674 E:1676 ||| .
Second ||| S:1676 E:1682 ||| LS
,  ||| S:1682 E:1684 ||| ,
NAA  ||| S:1684 E:1688 ||| NNP
metabolite  ||| S:1688 E:1699 ||| JJ
concentration  ||| S:1699 E:1713 ||| NN
was  ||| S:1713 E:1717 ||| VBD
increased  ||| S:1717 E:1727 ||| VBN
in  ||| S:1727 E:1730 ||| IN
thalamus  ||| S:1730 E:1739 ||| NN
of  ||| S:1739 E:1742 ||| IN
SAD ||| S:1742 E:1745 ||| NNP
,  ||| S:1745 E:1747 ||| ,
and  ||| S:1747 E:1751 ||| CC
choline  ||| S:1751 E:1759 ||| JJ
metabolite  ||| S:1759 E:1770 ||| JJ
concentrations  ||| S:1770 E:1785 ||| NNS
were  ||| S:1785 E:1790 ||| VBD
related  ||| S:1790 E:1798 ||| VBN
to  ||| S:1798 E:1801 ||| TO
measures  ||| S:1801 E:1810 ||| NNS
of  ||| S:1810 E:1813 ||| IN
social  ||| S:1813 E:1820 ||| JJ
anxiety ||| S:1820 E:1827 ||| NN
.  ||| S:1827 E:1829 ||| .
Lastly ||| S:1829 E:1835 ||| NNP
,  ||| S:1835 E:1837 ||| ,
choline  ||| S:1837 E:1845 ||| JJ
metabolite  ||| S:1845 E:1856 ||| JJ
concentration  ||| S:1856 E:1870 ||| NN
in  ||| S:1870 E:1873 ||| IN
the  ||| S:1873 E:1877 ||| DT
caudate  ||| S:1877 E:1885 ||| NN
and  ||| S:1885 E:1889 ||| CC
putamen  ||| S:1889 E:1897 ||| NNS
showed  ||| S:1897 E:1904 ||| VBD
changes  ||| S:1904 E:1912 ||| NNS
in  ||| S:1912 E:1915 ||| IN
relation  ||| S:1915 E:1924 ||| NN
to  ||| S:1924 E:1927 ||| TO
measures  ||| S:1927 E:1936 ||| NNS
of  ||| S:1936 E:1939 ||| IN
social  ||| S:1939 E:1946 ||| JJ
anxiety ||| S:1946 E:1953 ||| NN
.  ||| S:1953 E:1955 ||| .
These  ||| S:1955 E:1961 ||| DT
findings  ||| S:1961 E:1970 ||| NNS
are  ||| S:1970 E:1974 ||| VBP
consistent  ||| S:1974 E:1985 ||| JJ
with  ||| S:1985 E:1990 ||| IN
evidence  ||| S:1990 E:1999 ||| NN
that  ||| S:1999 E:2004 ||| IN
the  ||| S:2004 E:2008 ||| DT
reward ||| S:2008 E:2014 ||| FW
/ ||| S:2014 E:2015 ||| FW
avoidance  ||| S:2015 E:2025 ||| FW
basal  ||| S:2025 E:2031 ||| FW
ganglia  ||| S:2031 E:2039 ||| FW
circuitry ||| S:2039 E:2048 ||| FW
,  ||| S:2048 E:2050 ||| ,
as  ||| S:2050 E:2053 ||| RB
well  ||| S:2053 E:2058 ||| RB
as  ||| S:2058 E:2061 ||| IN
the  ||| S:2061 E:2065 ||| DT
glutamatergic  ||| S:2065 E:2079 ||| JJ
system ||| S:2079 E:2085 ||| NN
,  ||| S:2085 E:2087 ||| ,
play  ||| S:2087 E:2092 ||| VB
a  ||| S:2092 E:2094 ||| DT
role  ||| S:2094 E:2099 ||| NN
in  ||| S:2099 E:2102 ||| IN
mediating  ||| S:2102 E:2112 ||| JJ
SAD  ||| S:2112 E:2116 ||| NN
symptoms ||| S:2116 E:2124 ||| NNS
.  ||| S:2124 E:2126 ||| .
